The Journal of Rheumatology Antibodies in Patients with Dermatomyositis HLA-DRB 1 Alleles as Genetic Risk Factors for the Development of Anti-MDA 5
Akinori Kimura,Lingyun Sun,Zhiyong Chen,Yan Wang,Masataka Kuwana,Xue Xu,Xuebing Feng
2017-01-01
Abstract:Objective. Patients with polymyositis/dermatomyositis (PM/DM) who express anti-melanoma differentiation associated protein 5 (anti-MDA5) antibodies frequently present with interstitial lung disease (ILD). The aim of this study was to investigate the association of HLA-DRB1 with anti-MDA5 expression in PM/DM. Methods. The frequency of DRB1 alleles was compared among 70 patients with PM, 104 patients with DM, and 400 healthy controls in a Han Chinese population. Results. Frequencies of DRB1*04:01 [17.0% vs 1.3%, corrected p value (pc) = 3.8 × 10–8, OR 16.2, 95% CI 6.6–39.7] and *12:02 (42.6% vs 19.3%, pc = 0.008, OR 3.1, 95% CI 1.7–5.7) were significantly higher in anti-MDA5–positive patients with PM/DM compared with the controls. The frequencies of DRB1*04:01 (p = 5.2 × 10–6, OR 17.1, 95% CI 5.3–54.9) and *12:02 (p = 3.8 × 10–4, OR 3.1, 95% CI 1.7–5.7) in anti-MDA5–positive patients with DM-ILD were higher than in the controls, whereas the frequencies of DRB1*04:01 and *12:02 did not differ between the anti-MDA5– negative patients with DM-ILD and controls. No difference in the frequency of DRB1 alleles, other than *04:01, carrying the “shared epitope” (SE), i.e., *01:01, *01:02, *04:05, and *10:01, was observed between the controls and patients with DM stratified by the presence of anti-MDA5 and ILD. Conclusion. DRB1*04:01 and *12:02 confer susceptibility to anti-MDA5 antibody production in DM, which cannot be explained by the SE hypothesis. (J Rheumatol First Release July 15 2017; doi:10.3899/jrheum.170165) Key Indexing Terms: POLYMYOSITIS DERMATOMYOSITIS INTERSTITIAL LUNG DISEASE HUMAN LEUKOCYTE ANTIGEN ANTI-MELANOMA DIFFERENTIATION-ASSOCIATED GENE 5 ANTIBODY From the Department of Rheumatology and Immunology, and Department of Clinical Laboratory, the Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan. Supported by the National Natural Science Foundation of China (to ZC, NO. 81302556). Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health (to ZC, NO. ZKX16039). Z. Chen, MD, PhD, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School; Y. Wang, MD, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; X. Xu, MD, PhD, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School; W. Hu, MD, Department of Clinical Laboratory, the Affiliated Drum Tower Hospital, Nanjing University Medical School; X. Feng, MD, PhD, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School; H. Wang, MD, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School; A. Kimura, MD, PhD, Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University; L. Sun, MD, PhD, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School. Address correspondence to Dr. A. Kimura, Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. E-mail: akitis@mri.tmd.ac.jp; or Dr. L. Sun, Department of Rheumatology and Immunology, Drum Tower Clinical College of Nanjing Medical University, 321 Zhongshan Road, Nanjing, 210008, China. E-mail: lingyunsun2012@163.com Accepted for publication May 25, 2017. Polymyositis (PM) and dermatomyositis (DM) are auto immune diseases characterized by inflammation of skeletal muscle and other organ systems1. Disease-related death is generally associated with malignancy and/or interstitial lung disease (ILD), and a high mortality rate of patients with PM/DM has been confirmed in the Chinese population2. Myositis-specific autoantibodies (MSA) are a group of autoantibodies specifically found in PM/DM, but not in other autoimmune diseases. Studies have revealed that stratification of PM/DM according to the presence of MSA is useful because these autoantibodies are usually expressed in a mutually exclusive fashion in PM/DM and are closely Rheumatology The Journal of on July 17, 2017 Published by www.jrheum.org Downloaded from associated with the clinical phenotype3. Patients with DM who are positive for anti-melanoma differentiationassociated gene 5 (MDA5) antibody frequently have rapidly progressive ILD (RP-ILD), and their 6-month survival rate is only 41%4, demonstrating the poor prognosis of this clinical entity. Both genetic and environmental factors may be involved in the etiopathology of PM/DM. The first genome-wide association study of DM revealed a strong signal in the MHC region5. It has also been reported that the presence of ILD and MSA in patients with DM is largely controlled by the HLA class II haplotype, rather than by the myositis subtype6. In previous studies, we reported the high risk of DM patients with anti-MDA5 antibodies for developing RP-ILD and for high mortality4. We also observed a significantly higher frequency of anti-MDA5 antibodies in Chinese patients when compared with Japanese patients7. To date, only 1 study has investigated the association of anti-MDA5 expression with HLA-DRB1; in that study, DRB1*01:01 and *04:05 were reported to be associated with anti-MDA5 positivity in Japanese patients with DM8. However, because the number of participants was only 17, the findings should be replicated in other cohorts to confirm the association. To clarify the HLA-linked genetic factor for anti-MDA5, we performed an association study of HLA-DRB1 with anti-MDA5 antibodies in a Han Chinese population. Our study suggested that DRB1*04:01 and *12:02 are genetic predisposing factors for anti-MDA5 antibody production in DM. MATERIALS AND METHODS Participants. A total of 574 participants, consisting of 104 patients with DM, 70 patients with PM, and 400 healthy controls, were enrolled. All participants were of Han ethnicity and were from the Affiliated Drum Tower Hospital, Nanjing, China. Diagnosis of probable or definite PM, classic DM, and clinically amyopathic DM was made, as described previously4,9. Four hundred healthy controls with no history of autoimmune diseases were recruited from the health examination center of Drum Tower hospital. This study was approved by the Ethics Committee of Affiliated Drum Tower Hospital, Nanjing University Medical School (2015004), and written informed consent was obtained from each participant. HLA-DRB1 genotyping and anti-MDA5 antibody detection. Genotyping of HLA-DRB1 was performed using the sequencing-based typing method on a GeneAmp PCR System 9700 (Applied Biosystems). Sequencing data were collected using a 3730XL Genetic Analyzer (Applied Biosystems) and DRB1 allele assignments were interpreted using uTYPE Dx Sequencing Analysis Software (Thermo Fisher Scientific). Levels of anti-MDA5 were measured using recombinant MDA5 antigen, as described previously. This ELISA method showed an analytical sensitivity of 85% and analytical specificity of 100%, in comparison with the gold standard immunoprecipitation